Athenex, Inc. Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis
BUFFALO, N.Y., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today …